ESR1 and prostate carcinoma: As the imidazopyridines analyzed for the inhibition of clonal expansion of ER+ breast cancer cells also inhibited proliferation of AR+ prostate cancer cells (Supplementary Table S1), it is possibility that these compounds function through a common antitumor pathway.